Reported resultsCompany-reported
What was reported
SEATTLE — August 10, 2026 — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the second quarter 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 10, 2026 · Open the source ↗
What the evidence supports
Sana Biotechnology published its results for the period in a press release furnished to the SEC (Form 8-K, Item 2.02).
What remains unknown
Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineSana Biotechnology Reports Second Quarter 2026 Financial Results and Business UpdatesU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 10, 2026 · Open the source ↗
Press release lead paragraphSEATTLE — August 10, 2026 — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the second quarter 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 10, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:53 UTC
Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.